OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
4
Results
Show all
Save search
Copy query
Show results for
Unknown
(4)
Publication Date
Release Date
2025
(3)
2011
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).
Not available
S-EPMC12378973
|
biostudies-literature
Cite
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Not available
S-EPMC3166604
|
biostudies-literature
Cite
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.
Not available
S-EPMC11761902
|
biostudies-literature
Cite
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial.
Not available
S-EPMC12146809
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets